Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone Extension in MCI due to AD
NCT02284906Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of pioglitazone in mild cognitive impairment due to Alzheimer's disease, sponsored by Takeda. Started Feb 2015; status: terminated.
02
Drugs
pioglitazone
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NCT02284906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284906.